Advertisement
UK markets close in 8 hours 3 minutes

  • FTSE 100

    8,093.48
    +53.10 (+0.66%)
     

  • FTSE 250

    19,629.32
    -90.05 (-0.46%)
     

  • AIM

    754.97
    +0.28 (+0.04%)
     

  • GBP/EUR

    1.1659
    +0.0015 (+0.12%)
     

  • GBP/USD

    1.2494
    +0.0032 (+0.26%)
     

  • Bitcoin GBP

    51,464.30
    -2,071.56 (-3.87%)
     

  • CMC Crypto 200

    1,390.53
    +7.96 (+0.58%)
     

  • S&P 500

    5,071.63
    +1.08 (+0.02%)
     

  • DOW

    38,460.92
    -42.77 (-0.11%)
     

  • CRUDE OIL

    82.93
    +0.12 (+0.14%)
     

  • GOLD FUTURES

    2,333.30
    -5.10 (-0.22%)
     

  • NIKKEI 225

    37,628.48
    -831.60 (-2.16%)
     

  • HANG SENG

    17,298.72
    +97.45 (+0.57%)
     

  • DAX

    18,029.01
    -59.69 (-0.33%)
     

  • CAC 40

    8,086.37
    -5.49 (-0.07%)
     
Property:

How to sell your home

Top tips from property investors

WHO group backs Sanofi's vaccine in areas with high dengue rates

Reuters - UK Focus

GENEVA, April 15 (Reuters) - The World Health Organization's expert group on immunisation said on Friday it recommended that countries consider introducing Sanofi (LSE: 0O59.L - news) 's dengue vaccine Dengvaxia in areas where prevalence of the virus was 50 percent or higher.

Vaccination should be done between the ages of nine and 11, but efficacy improved as people got older, Jon Abramson, chairman of the WHO's Strategic Advisory Group of Experts on immunisation (SAGE) told a news conference in Geneva.

The vaccine needs to be administered in a three-dose series and SAGE does not recommend its use before 9-years-old, which it said was consistent with current labelling. (Reporting by Tom Miles; Editing by Alison Williams)